$ImmunityBio (IBRX.US)$ 1. Expected Approval for Bladder Can...
$ImmunityBio (IBRX.US)$ 1. Expected Approval for Bladder Cancer Sales in Europe and the UK by February
- Sales will expand across Europe immediately upon approval, serving as a direct catalyst for an explosive revenue surge in 2026.
2. Expansion of Indications and New Biologics License Application (BLA)
- Expectations for NSCLC (Non-Small Cell Lung Cancer) BLA submission and approval: The BLA submission to the U.S. FDA to expand the indication for lung cancer is scheduled to proceed.
3. Approval for Papillary Bladder Cancer (NMIBC)
- Approval is scheduled to broaden the prescription range of ANKTIVA to include not only existing CIS patients but also those with papillary tumors.
4. Colon Cancer Vaccine Data
- Clinical results for the world’s first cancer prevention vaccine targeting Lynch Syndrome families are set to be announced.
5. Additional Clinical Results for Brain Cancer (GBM)
- Follow-up results or news of expanded clinical trials for brain cancer, which previously showed a survival rate of over 70%, will lead to a re-evaluation of the company’s value.
In addition
- There is a high possibility of news regarding substantial large-scale investments, such as the construction of local production facilities in Saudi Arabia or additional inflows of Middle Eastern capital.
- Sales will expand across Europe immediately upon approval, serving as a direct catalyst for an explosive revenue surge in 2026.
2. Expansion of Indications and New Biologics License Application (BLA)
- Expectations for NSCLC (Non-Small Cell Lung Cancer) BLA submission and approval: The BLA submission to the U.S. FDA to expand the indication for lung cancer is scheduled to proceed.
3. Approval for Papillary Bladder Cancer (NMIBC)
- Approval is scheduled to broaden the prescription range of ANKTIVA to include not only existing CIS patients but also those with papillary tumors.
4. Colon Cancer Vaccine Data
- Clinical results for the world’s first cancer prevention vaccine targeting Lynch Syndrome families are set to be announced.
5. Additional Clinical Results for Brain Cancer (GBM)
- Follow-up results or news of expanded clinical trials for brain cancer, which previously showed a survival rate of over 70%, will lead to a re-evaluation of the company’s value.
In addition
- There is a high possibility of news regarding substantial large-scale investments, such as the construction of local production facilities in Saudi Arabia or additional inflows of Middle Eastern capital.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
